Sitravatinib
- Generic Name
- Sitravatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
- Conditions
- Metastatic Cervical Cancer
- Interventions
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: sitravatinib-matching placeboDrug: tislelizumab-matching placebo
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05564338
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Grupo Español Multidisciplinar de Melanoma
- Target Recruit Count
- 16
- Registration Number
- NCT05542342
- Locations
- 🇪🇸
Hospital Universitario Virgen de la Macarena, Sevilla, Andalucia, Spain
🇪🇸Hospital General Universitario de Valencia, Valencia, Spain
🇪🇸Hospital Universitario la Paz, Madrid, Spain
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 96
- Registration Number
- NCT05461794
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
- Conditions
- Recurrent Endometrial CancerSolid Tumors
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Haider Mahdi
- Registration Number
- NCT05419817
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05255276
- Locations
- 🇺🇸
Labcorp Drug Development Clinical Research Unit, Dallas, Texas, United States
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
- Conditions
- Lung Cancer, Small Cell
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05228496
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 5
- Registration Number
- NCT05176925
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 37
- Registration Number
- NCT05104801
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study to Explore the Effect of Acid-reducing Agents
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04935112
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.